Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 20:31 | 2026-04-27 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $37.78 | 1,576 | $59,541 | 175,342 |
| 2026-04-29 20:32 | 2026-04-28 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $159.16 | 1,000 | $159,162 | 6,666 |
| 2026-04-28 20:05 | 2026-04-24 | NBP | NovaBridge Biosciences | Hagler Mark Arnold | Officer | BUY | $2.51 | 230,000 | $577,300 | 230,000 |
| 2026-04-29 01:41 | 2026-04-16 | TRAW | Traws Pharma, Inc. | ORBIMED ADVISORS LLC | 10% owner | BUY | $1.67 | 597,729 | $998,207 | 1,203,250 |
| 2026-04-28 23:49 | 2026-04-27 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer | OPT+S | $22.88 | 5,500 | $125,830 | 55,286 |
| 2026-04-28 23:37 | 2026-04-27 | ABT | ABBOTT LABORATORIES | STARKS DANIEL J | Director | BUY | $92.65 | 10,000 | $926,537 | 6,751,103 |
| 2026-04-28 22:00 | 2026-04-28 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer, 10% owner | BUY | $4.52 | 10,000 | $45,180 | 3,062,000 |
| 2026-04-28 22:04 | 2026-04-27 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $568.81 | 9,500 | $5,403,685 | 40,513 |
| 2026-04-28 21:30 | 2026-04-27 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $568.83 | 10,000 | $5,688,319 | 18,876 |
| 2026-04-28 20:28 | 2026-04-27 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $162.64 | 1,000 | $162,641 | 7,666 |
| 2026-04-27 23:27 | 2026-04-23 | ACRS | Aclaris Therapeutics, Inc. | Leonard Braden Michael | 10% owner | SELL | $4.53 | 300,000 | $1,359,000 | 13,950,000 |
| 2026-04-27 22:15 | 2026-04-23 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $18.47 | 384,549 | $7,101,120 | 1,206,026 |
| 2026-04-27 21:34 | 2026-04-23 | ABT | ABBOTT LABORATORIES | Boudreau Philip P | Officer | BUY | $91.50 | 2,200 | $201,300 | 2,200 |
| 2026-04-27 21:33 | 2026-04-21 | HEPA | Hepion Pharmaceuticals, Inc. | Purcell Michael J. | Director | BUY | $0.04 | 1,250,000 | $50,000 | 1,250,000 |
| 2026-04-27 20:52 | 2026-04-24 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $159.56 | 1,000 | $159,556 | 8,666 |
| 2026-04-27 20:39 | 2026-04-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $564.81 | 9,500 | $5,365,678 | 40,513 |
| 2026-04-27 20:26 | 2026-04-23 | IRD | Opus Genetics, Inc. | Gagnon Robert E. | Officer | SELL | $5.18 | 7,842 | $40,658 | 592,158 |
| 2026-04-27 20:26 | 2026-04-23 | IRD | Opus Genetics, Inc. | Jayagopal Ashwath | Officer | SELL | $5.19 | 7,542 | $39,156 | 509,233 |
| 2026-04-27 20:27 | 2026-04-23 | IRD | Opus Genetics, Inc. | Magrath George | Director, Officer | SELL | $5.22 | 9,511 | $49,647 | 1,741,344 |
| 2026-04-27 20:27 | 2026-04-23 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | Officer | SELL | $5.20 | 1,641 | $8,540 | 188,671 |
| 2026-04-27 20:28 | 2026-04-23 | IRD | Opus Genetics, Inc. | SCHACHLE JOSEPH K | Officer | SELL | $5.22 | 4,697 | $24,519 | 296,084 |
| 2026-04-27 20:28 | 2026-04-23 | IRD | Opus Genetics, Inc. | YERXA BENJAMIN R | Director, Officer | SELL | $5.24 | 7,470 | $39,121 | 711,535 |
| 2026-04-27 19:13 | 2026-04-23 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.28 | 33,215 | $9,337 | 88,377 |
| 2026-04-27 10:24 | 2026-04-21 | HEPA | Hepion Pharmaceuticals, Inc. | Stetz Gary S. | Director, Officer | BUY | $0.04 | 1,250,000 | $50,000 | 1,250,000 |
| 2026-04-27 10:24 | 2026-04-21 | HEPA | Hepion Pharmaceuticals, Inc. | Appajosyula Sireesh | Director | BUY | $0.04 | 1,250,000 | $50,000 | 1,250,000 |
| 2026-04-27 10:24 | 2026-04-21 | HEPA | Hepion Pharmaceuticals, Inc. | LoPriore Vincent S | Director, Officer, 10% owner | BUY | $0.04 | 6,250,000 | $250,000 | 6,250,000 |
| 2026-04-25 00:41 | 2026-04-23 | PCRX | Pacira BioSciences, Inc. | Cross Shawn | Officer | OPT+S | $25.16 | 12,941 | $325,596 | 105,341 |
| 2026-04-24 22:38 | 2026-04-23 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Hamilton James C | Officer | SELL | $75.00 | 10,000 | $750,000 | 226,958 |
| 2026-04-24 22:44 | 2026-04-22 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Apel Daniel Joseph | Officer | SELL | $71.35 | 13,095 | $934,285 | 162,905 |
| 2026-04-24 22:10 | 2026-04-23 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Neman-Ebrahim Yousha | Officer | BUY | $4.88 | 500 | $2,440 | 134,760 |
| 2026-04-24 22:00 | 2025-04-15 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | GARNETT KEITHLY | Officer | BUY | $5.38 | 300 | $1,614 | 241,200 |
| 2026-04-24 20:31 | 2026-04-24 | UTHR | UNITED THERAPEUTICS Corp | PATUSKY CHRISTOPHER | Director | OPT+S | $569.00 | 2,910 | $1,655,790 | 1,490 |
| 2026-04-24 20:32 | 2026-04-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $572.35 | 9,500 | $5,437,339 | 40,513 |
| 2026-04-24 20:32 | 2026-04-22 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $572.34 | 10,000 | $5,723,438 | 18,876 |
| 2026-04-24 20:15 | 2026-04-23 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $166.28 | 1,000 | $166,284 | 9,666 |
| 2026-04-24 18:09 | 2026-04-22 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | $30.05 | 7,100 | $213,382 | 388,067 |
| 2026-04-24 16:18 | 2026-04-22 | PHVS | Pharvaris N.V. | Lesage Anne | Officer | OPT+S | $30.05 | 14,700 | $441,726 | 56,450 |
| 2026-04-24 15:27 | 2026-04-22 | PHVS | Pharvaris N.V. | Lu Peng | Officer | OPT+S | $30.05 | 7,101 | $213,405 | 66,083 |
| 2026-04-24 01:25 | 2026-04-22 | PMN | ProMIS Neurosciences Inc. | Kirwin Patrick D. | Director | BUY | $11.33 | 4,000 | $45,320 | 4,653 |
| 2026-04-24 01:34 | 2026-04-23 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer, 10% owner | BUY | $4.90 | 10,000 | $49,000 | 3,052,000 |
| 2026-04-24 01:01 | 2026-04-22 | AXSM | Axsome Therapeutics, Inc. | Maizel Ari | Officer | OPT+S | $182.42 | 7,500 | $1,368,150 | 0 |
| 2026-04-23 23:30 | 2026-04-21 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $54.79 | 21,120 | $1,157,091 | 95,880 |
| 2026-04-23 22:50 | 2026-04-21 | PRLD | Prelude Therapeutics Inc | Bonita David P | Director, 10% owner | BUY | $4.44 | 2,815,315 | $12,499,999 | 1,126,126 |
| 2026-04-23 22:48 | 2026-04-21 | PRLD | Prelude Therapeutics Inc | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $4.44 | 2,815,315 | $12,499,999 | 1,126,126 |
| 2026-04-23 21:20 | 2026-04-21 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $70.91 | 2,850 | $202,094 | 394,070 |
| 2026-04-23 20:53 | 2026-04-22 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $576.56 | 9,500 | $5,477,367 | 40,513 |
| 2026-04-23 20:05 | 2026-04-22 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Officer | SELL | $39.09 | 9,100 | $355,719 | 113,987 |
| 2026-04-23 20:15 | 2026-04-21 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $20.01 | 10,952 | $219,169 | 4,196,573 |
| 2026-04-23 20:19 | 2026-04-22 | BLTE | BELITE BIO, INC | MATA NATHAN L. | Officer | SELL | $170.38 | 1,000 | $170,384 | 10,666 |
| 2026-04-23 19:43 | 2026-04-22 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | SELL | $0.30 | 11,982 | $3,595 | 121,592 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.